BioSpace News Archive

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 12:40 p.m. Pacific Time.

MaxCyte, Inc. announced that, on February 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 204,500 shares of MaxCyte’s common stock to eight newly hired employees.

Stealth BioTherapeutics Corp announced that on February 11, 2022, it received a letter from The Nasdaq Stock Market LLC, notifying the Company that it is currently not in compliance with the minimum Market Value of Publicly Held Shares requirement based upon Nasdaq’s review of the Company’s MVPHS for the 30 consecutive business days through February 10, 2022.

Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), today announced the enrollment and dosing of first patient in China in its multi-regional phase III clinical trial (NCT04869228) of proxalutamide for the treatment of COVID-19 outpatients in the Third People’s Hospital of Shenzhen in China on 10 February 2022.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided financial guidance for 2022.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from its Phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD).

Vor Biopharma, a clinical-stage cell and genome engineering company, announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference.

Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), today announced that it received notice from its exclusive licensing partner in Japan, Maruho Co., Ltd. (“Maruho”), that Japan’s Ministry of Health, Labor and Welfare (“MHLW”) approved Rapifort® Wipes 2.5% (glycopyrronium tosylate hydrate) for the treatment of primary axillary hyperhidrosis.

NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel Yitzhaki, Director of the Israel Institute for Biological Research, who spoke at the Eli Hurvitz Institute for Strategic Management of Tel Aviv University.

Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that the company will be presenting at the upcoming 2022 BIO CEO & Investor Conference.